Physician
Oncology
Dr. Farshid Dayyani, MD
|
|
Give Review
Farshid Dayyani is an expert in the field of Oncology. Farshid Dayyani is also published. He has 27 publications published. The lastest publication: "Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).' He accepts all Medicare patients.
Publications
- Phase II trial of vatalanib in patients with advanced or metastatic Pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
- Management of Advanced Primary Urethral Carcinomas.
- Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists(☆).
- Ligand-independent activation of MET through IGF-1/IGF-1R signaling.
- Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate Cancer by decreasing activated survival pathways.
- Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate Cancer.
- Plasmacytoid Urothelial Carcinomas - A Chemo-sensitive Cancer with Poor Prognosis, and Peritoneal Carcinomatosis.
- The role of HGF/c-Met signaling in prostate Cancer progression and c-Met inhibitors in clinical trials.
- Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer.
- Prediction model for mortality after intracranial hemorrhage in patients with leukemia.
- Steps in prostate Cancer progression that lead to bone metastasis.
- Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
- Meta-analysis of the impact of human papillomavirus (HPV) on Cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC).
- Cause of death in patients with lower-risk myelodysplastic syndrome.
- Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.
- HIV-associated multicentric Castleman's disease.
- Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival.
- Multicentric Castleman's disease masquerading as HIV-related Lymphoma.
- Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia.
- The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation o...
- Impact of type-I-interferon on monocyte subsets and their differentiation to dendritic cells. An in vivo and ex vivo study in multiple sclerosis patients treated with ...
- Autologous stem-cell transplantation restores the functional properties of CD14+CD16+ monocytes in patients with myeloma and Lymphoma.
- Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients.
- Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes.
- The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF.
- Selective mobilization of CD14(+)CD16(+) monocytes by exercise.
Schools
Ludwig Maximiliams University Medical Faculty
Beth Israel Deaconess Med Ctr Harvard
University Texas MD Anderson Cancer Center
Harvard University Massachusetts General Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
Beth Israel Deaconess Medical Center -
Ludwig Maximilian University of Munich Faculty of Medicine
Drug Facts
| NPI NUMBER | 1376710434 | |
| NPPES Provider LastName | DAYYANI | |
| NPPES Provider FirstName | FARSHID | |
| NPPES Provider ZIPCode | 852342165 | |
| NPPES Provider State | AZ | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 365.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 22.0 | |
| Percent Opioid Claims | 6.03 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1376710434 |
| Last Name Of The Provider | DAYYANI |
| First Name Of The Provider | FARSHID |
| View All |
Similar Doctors
|
Dr. Edgardo C. Rivera, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Puneet Bhalla, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Santosh K. Rao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wishwdeep S. Dhillon, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Klaus W. Wagner, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sumeet K. Mendonca, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jade Homsi, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Madappa N. Kundranda, MD
This Doctor is OpenDoctor Recommended.
|